CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 + MK-677 Synergy: Dosing & Timing Protocol

Real Peptides Research TeamEditorial

Updated April 30, 202611 min read

59 WORDS

Short answer

Key takeaways

CJC-1295 with DAC has a 6–8 day half-life and should be dosed once weekly at 1–2mg subcutaneously to maintain sustained GH baseline without cumulative overshooting.
MK-677 should be dosed at 12.5–25mg orally in the evening, 4–5 nights per week with 2–3 off days to prevent GHSR-1a receptor desensitization that reduces GH response by 30–40% after 14 days of daily dosing.
The synergy between CJC-1295 and MK-677 arises because they activate non-overlapping pathways: GHRH signaling (CJC-1295) versus ghrelin receptor activation (MK-677), allowing additive effects without receptor competition.
Evening MK-677 administration aligns with natural nocturnal GH secretion peaks, producing 90-minute to 6-hour GH elevation windows that overlap endogenous pulsatile release for maximum synergy.
Optimal weekly stack structure: CJC-1295 (1–2mg) on Monday morning, MK-677 (25mg) on Tuesday, Thursday, Friday, Saturday evenings, with Sunday-Monday as receptor recovery days before the next CJC injection.

CJC-1295 and MK-677 produce profoundly different growth hormone (GH) release patterns that, when properly timed, generate amplification effects neither compound achieves alone. CJC-1295 (DAC) is a GHRH analog that extends endogenous GH pulse duration by binding albumin and resisting enzymatic degradation. Half-life stretches to 6–8 days, creating sustained baseline GH elevation without the sharp peaks that trigger negative feedback. MK-677 (ibutamoren) is a ghrelin mimetic that acts on the GHSR-1a receptor to dramatically increase pulse amplitude. Single doses elevate serum GH by 50–100% within 90 minutes but rapidly downregulate if dosed continuously at high frequency. The synergy emerges because CJC-1295 maintains the signaling foundation while MK-677 delivers the acute surge. But only if you respect the receptor biology that governs both.

Our team has worked with researchers optimizing peptide protocols since 2018, and the gap between effective stacking and wasted compounds comes down to three factors: receptor kinetics, dosing intervals, and the metabolic context each peptide requires to function.

What is the optimal dosing and timing strategy for combining CJC-1295 and MK-677?

CJC-1295 should be dosed at 1–2mg subcutaneously once weekly, administered on a fixed day to maintain consistent baseline GH elevation. MK-677 should be dosed at 12.5–25mg orally in the evening, 4–5 nights per week with 2–3 non-dosing days to prevent receptor desensitization. CJC-1295 establishes the sustained foundation; MK-677 provides the acute amplitude boost. The weekly CJC injection avoids the pulsatile disruption that daily GHRH dosing creates, while intermittent MK-677 preserves ghrelin receptor sensitivity.

The common mistake is treating both compounds as 'daily maintenance' peptides. Stacking them at high frequency every day for weeks. CJC-1295 with DAC doesn't require daily dosing because the drug-albumin complex maintains therapeutic plasma levels across 6–8 days. MK-677 dosed daily at 25mg causes GHSR-1a receptor downregulation within 10–14 days, blunting the GH response by 30–40%. This article covers the receptor mechanisms that dictate stacking protocols, the specific dosing windows that maximize synergy, and the metabolic timing factors that determine whether the compounds amplify or interfere with each other.

Why CJC-1295 and MK-677 Stack: Complementary Mechanisms

CJC-1295 extends growth hormone-releasing hormone (GHRH) signaling by resisting dipeptidyl peptidase-IV (DPP-IV) degradation. The enzyme that normally cleaves native GHRH within 7 minutes of secretion. Adding a drug affinity complex (DAC) allows CJC-1295 to bind serum albumin, creating a half-life of 6–8 days versus the 30-minute half-life of unmodified GHRH. This produces sustained baseline GH elevation without the sharp peaks that trigger somatostatin release (the negative feedback loop that suppresses further GH secretion). Research published by Teichman et al. in the Journal of Clinical Endocrinology & Metabolism demonstrated that single-dose CJC-1295 DAC elevated mean 24-hour GH levels by 200–300% for up to one week, with no rebound suppression. A pattern unachievable with pulsatile GHRH administration.

MK-677 operates through an entirely different pathway: it mimics ghrelin, the 'hunger hormone' that binds growth hormone secretagogue receptor 1a (GHSR-1a) in the hypothalamus and pituitary. Ghrelin signaling triggers acute, high-amplitude GH pulses. Single 25mg doses of MK-677 elevate serum GH by 50–100% within 90 minutes and maintain elevation for 4–6 hours. The amplitude is consistently higher than baseline secretion, but the effect diminishes with continuous daily dosing because GHSR-1a receptors internalize and downregulate when persistently activated. The synergy emerges because CJC-1295 sustains the GHRH-mediated baseline while MK-677 delivers the ghrelin-mediated surge. Two non-overlapping pathways that don't compete for the same receptor.

We've found that stacking protocols fail when researchers treat both compounds as interchangeable 'GH boosters' without accounting for their distinct pharmacokinetics. CJC-1295's week-long half-life means daily injections create cumulative plasma levels that overshoot therapeutic range and trigger compensatory IGF-1 feedback suppression. MK-677's rapid receptor desensitization means daily dosing past two weeks produces diminishing returns. The optimal stack respects both kinetics: weekly CJC-1295 for sustained elevation, intermittent MK-677 for preserved amplitude.

CJC-1295 Dosing Protocol: Weekly Administration

CJC-1295 with DAC should be administered subcutaneously at 1–2mg once weekly, injected on the same day each week to maintain consistent baseline GH elevation. The 6–8 day half-life means therapeutic plasma concentrations persist throughout the dosing interval. Multiple injections per week create unnecessary accumulation without additional GH benefit. Research from Ionescu and Frohman (2006) found that single-dose CJC-1295 (2mg) elevated mean GH and IGF-1 levels for 6–9 days post-injection, with peak effects occurring 48–72 hours after administration and gradual return to baseline by day 8–10.

Subcutaneous injection site rotation (abdomen, thigh, deltoid) prevents localized lipohypertrophy that can impair absorption over time. Inject 1–2 inches away from the navel and rotate quadrants weekly. Our experience working with long-term peptide researchers shows that consistent injection timing. Same day, same approximate time. Produces more stable IGF-1 levels than sporadic dosing, even when total weekly dose is identical.

Dosage titration is unnecessary for most research applications. Starting at 1mg weekly establishes baseline response; if IGF-1 elevation is suboptimal after 3–4 weeks, increase to 1.5mg, then 2mg if needed. Doses above 2mg weekly do not produce proportional GH increases and elevate the risk of peripheral edema and insulin resistance (common with sustained supraphysiological IGF-1). CJC1295 Ipamorelin 5MG 5MG formulations from Real Peptides maintain potency across multiple freeze-thaw cycles when stored at -20°C before reconstitution.

MK-677 Dosing and Timing: Intermittent Protocol

MK-677 should be dosed orally at 12.5–25mg in the evening, 4–5 nights per week with 2–3 non-consecutive off days built into the weekly schedule. Evening administration aligns with natural nocturnal GH secretion patterns. Endogenous GH pulses peak 60–90 minutes after sleep onset, and MK-677's GH release window (90 minutes to 6 hours post-dose) overlaps this period when dosed 1–2 hours before bed. A study by Svensson et al. in the Journal of Clinical Endocrinology & Metabolism found that 25mg MK-677 dosed at night increased mean overnight GH secretion by 97% and morning serum IGF-1 by 55% after 7 days, with no attenuation across the initial treatment period.

The intermittent dosing schedule. Not daily. Is critical to preserving ghrelin receptor sensitivity. GHSR-1a receptors desensitize under continuous agonist exposure: daily 25mg MK-677 for 14+ days reduces peak GH response by 30–40% compared to initial dosing, a phenomenon documented in multiple Phase 2 trials. Taking 2–3 off days per week allows receptor resensitization and prevents the appetite surge and insulin resistance that emerge with sustained high-dose ghrelin mimicry. Our team has consistently observed better sustained GH response with 4–5 days per week at 25mg than with 7 days per week at 12.5mg. The latter produces tolerance faster than the former despite lower total weekly dose.

MK-677 causes transient insulin resistance during the 4–6 hour GH elevation window. Fasting glucose can rise 10–15 mg/dL within 2 hours of dosing. Taking MK-677 on an empty stomach (2+ hours after last meal) and avoiding carbohydrate intake for 1–2 hours post-dose minimizes this effect. MK 677 capsules from Real Peptides are formulated for rapid gastric absorption, with measurable GH elevation detectable within 45–60 minutes of oral administration.

CJC-1295 and MK-677 Synergy Timing: Weekly Stack Structure

Protocol Element	CJC-1295	MK-677	Synergy Rationale	Professional Assessment
Dosing Frequency	Once weekly (same day)	4–5 nights per week (non-consecutive off days)	CJC-1295 provides sustained baseline; MK-677 adds intermittent amplitude surges without receptor burnout	Weekly CJC + intermittent MK-677 prevents both compounds from interfering with each other's receptor kinetics
Optimal Timing	Monday morning (or fixed weekly day)	Evening, 1–2 hours before bed	CJC-1295 establishes foundation early in week; MK-677 aligns with nocturnal GH peaks	Starting CJC early in the week ensures stable baseline before first MK-677 dose
Dose Range	1–2mg subcutaneous	12.5–25mg oral	CJC at therapeutic minimum; MK-677 at proven efficacy threshold	Lower CJC dose (1mg) suits stack beginners; 25mg MK-677 is standard research dose
Peak Effect Window	48–72 hours post-injection, sustained 6–8 days	90 minutes to 6 hours post-dose	CJC maintains elevated baseline when MK-677 surges occur	Non-overlapping peak windows prevent simultaneous GH spikes that trigger somatostatin rebound
Off Days	None (weekly dosing = inherent recovery)	2–3 non-consecutive nights per week	CJC's long half-life requires no off days; MK-677 off days preserve GHSR-1a sensitivity	MK-677 tolerance builds faster than CJC tolerance. Intermittent dosing is non-negotiable
Bottom Line Assessment	Weekly CJC-1295 (1–2mg) on Monday + MK-677 (25mg) on Tuesday, Thursday, Friday, Saturday evenings = optimal synergy without receptor desensitization. The CJC injection anchors the week; MK-677 delivers 4 amplitude surges across 6 days, with Sunday-Monday as recovery window before next CJC dose.	This structure produces 200–300% baseline GH elevation from CJC plus 4 discrete 50–100% amplitude surges from MK-677 weekly. A pattern unachievable with either compound alone.

What If: CJC-1295 and MK-677 Scenarios

What If I Dose CJC-1295 More Than Once Per Week?

Reduce dosing frequency to once weekly or switch to CJC-1295 No DAC (half-life 30 minutes) if you need more frequent administration. CJC-1295 with DAC accumulates in plasma when dosed more than once weekly. The 6–8 day half-life means the second injection stacks on top of the first, creating sustained supraphysiological IGF-1 levels that trigger compensatory somatostatin release and blunt GH responsiveness. Research by Ionescu and Frohman found that bi-weekly CJC-1295 DAC dosing (2mg every 3–4 days) produced no additional GH benefit versus weekly dosing but increased edema and fasting glucose dysregulation. If your protocol requires more frequent GHRH signaling, use modified GRF 1-29 (CJC-1295 No DAC) at 100–200mcg 2–3 times daily instead. The short half-life prevents accumulation.

What If I Take MK-677 Every Day Without Off Days?

Expect diminished GH response after 10–14 days and consider cycling off entirely for 7–10 days to restore sensitivity. Daily MK-677 at 25mg causes progressive GHSR-1a receptor internalization. By week 3 of continuous dosing, peak GH elevation drops from 80–100% above baseline to 30–40% above baseline, and appetite stimulation intensifies (ghrelin's orexigenic effects persist even as GH effects wane). Taking 2–3 off days per week preserves receptor density and maintains the initial GH response across months of use. If you've already been dosing daily for 3+ weeks, stop MK-677 entirely for 7–10 days, then restart at 4–5 days per week.

What If I Experience Severe Water Retention on CJC-1295?

Reduce CJC-1295 dose to 1mg weekly or discontinue and reassess baseline insulin sensitivity before reintroducing. Peripheral edema and water retention are GH-mediated effects caused by sodium retention in renal tubules and increased capillary permeability. They occur in 10–15% of users at 2mg weekly CJC-1295 and are more common in individuals with pre-existing insulin resistance or metabolic syndrome. Lowering the dose to 1mg weekly reduces IGF-1 elevation by approximately 30%, which often resolves edema within 5–7 days. If edema persists at 1mg, discontinue CJC-1295 and evaluate fasting insulin and HbA1c. Undiagnosed insulin resistance amplifies GH's sodium-retaining effects.

The Clinical Truth About CJC-1295 and MK-677 Synergy

Here's the honest answer: most peptide stack failures aren't dose failures. They're timing failures. CJC-1295 and MK-677 work through entirely different mechanisms and half-lives, but the standard advice ('take both daily') treats them as interchangeable GH boosters. CJC-1295 with DAC lasts a week. Dosing it daily creates cumulative plasma levels that overshoot therapeutic range and trigger IGF-1 feedback suppression. MK-677 desensitizes its own receptor after 10–14 days of continuous dosing. Taking it every night produces tolerance faster than taking it 4–5 nights per week at the same dose. The synergy only exists if you respect the biology: weekly CJC for sustained baseline, intermittent MK-677 for preserved amplitude. Stack them wrong and you're not just wasting compounds. You're actively blunting the response you're trying to amplify.

Metabolic Context and Substrate Availability

Growth hormone's anabolic effects. Protein synthesis, lipolysis, tissue repair. Require substrate availability that most stack protocols ignore. GH elevates circulating free fatty acids and amino acids, but it can't synthesize them from nothing. Stacking CJC-1295 and MK-677 in a prolonged fasted state or severe caloric deficit produces elevated GH and IGF-1 levels without corresponding anabolic outcomes because the metabolic substrates for tissue growth aren't available. Research from Møller et al. in the Journal of Clinical Investigation demonstrated that GH administration during fasting increased lipolysis but suppressed protein synthesis. The body prioritized fuel mobilization over tissue repair.

Optimal metabolic context for CJC-1295 and MK-677 synergy includes adequate daily protein intake (1.6–2.2g per kg bodyweight), caloric intake at or slightly above maintenance, and carbohydrate timing that supports insulin sensitivity. MK-677 causes transient insulin resistance during its 4–6 hour GH elevation window. Dosing it in the evening after a moderate-carbohydrate meal (30–50g carbs) and then fasting overnight allows insulin sensitivity to recover by morning. CJC-1295's sustained GH elevation improves insulin sensitivity when paired with regular resistance training (3+ sessions per week) but worsens it in sedentary contexts.

Our experience working with research teams shows that the metabolic environment determines whether elevated GH translates into measurable body composition changes. Elevated GH in a caloric deficit produces fat loss but minimal lean mass gain. Elevated GH at maintenance calories with adequate protein produces lean mass gain and modest fat loss. Elevated GH in a surplus without training produces minimal body composition change and increased insulin resistance. The peptides create the hormonal environment. Substrate availability and training stimulus determine what happens inside that environment.

If the receptor kinetics concern you, test it before committing to a 12-week protocol. Run CJC-1295 alone for 4 weeks at 1mg weekly, track morning fasted IGF-1 at baseline and week 4, then add MK-677 at 25mg 4 nights per week for another 4 weeks and retest IGF-1. The data will show whether the synergy exists in your specific metabolic context. And whether intermittent MK-677 preserves the response better than daily dosing would.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 produces measurable GH elevation within 48–72 hours of the first subcutaneous injection, with peak IGF-1 levels typically occurring 3–5 days post-dose and remaining elevated for 6–8 days. MK-677 elevates serum GH within 60–90 minutes of oral administration, with peak GH levels occurring 2–3 hours post-dose and returning to baseline within 6–8 hours. The synergistic effect — sustained baseline elevation from CJC-1295 plus intermittent amplitude surges from MK-677 — becomes measurable after the first MK-677 dose taken 24–48 hours after the initial CJC-1295 injection.

Yes, but optimal timing separates them by 24–48 hours to allow CJC-1295's baseline elevation to establish before adding MK-677's amplitude surge. Injecting CJC-1295 on Monday morning and starting MK-677 on Tuesday evening allows the GHRH-mediated baseline to stabilize before the ghrelin-mediated pulse occurs, producing cleaner synergy than simultaneous dosing. There is no pharmacological interaction that prevents same-day use, but staggered timing produces more predictable GH kinetics and allows you to isolate which compound is responsible for any adverse effects that emerge.

The most common side effects include transient water retention and peripheral edema (10–15% of users), increased appetite from MK-677's ghrelin mimicry (affects nearly all users within 60–90 minutes of dosing), and mild fasting glucose elevation (10–15 mg/dL increase during MK-677's active window). Less common but documented effects include carpal tunnel symptoms from fluid retention, lethargy during MK-677's active window if dosed during the day, and insulin resistance markers (elevated fasting insulin, reduced glucose disposal) in individuals with pre-existing metabolic dysfunction. Rotating injection sites prevents lipohypertrophy; taking MK-677 in the evening minimizes appetite disruption; keeping total weekly CJC-1295 dose at or below 2mg reduces edema risk.

CJC-1295 and MK-677 stimulate endogenous GH production through the hypothalamic-pituitary axis, preserving natural pulsatility and feedback regulation, while exogenous recombinant human growth hormone (rhGH) suppresses endogenous production entirely through negative feedback. Peptide stacking produces lower peak GH levels (200–300% above baseline for CJC-1295, 50–100% amplitude surges for MK-677) compared to rhGH injections (which can elevate GH 500–1000% above baseline), but peptide-stimulated GH maintains physiological pulsatility patterns that reduce the risk of insulin resistance and organ hypertrophy associated with sustained supraphysiological rhGH. Cost is another factor: CJC-1295 and MK-677 together cost roughly one-tenth the price of pharmaceutical rhGH at equivalent IGF-1-elevating doses.

CJC-1295 with DAC does not require cycling because its once-weekly dosing prevents cumulative receptor desensitization — each injection clears before the next dose, maintaining GHRH receptor sensitivity across months of use. MK-677 benefits from built-in cycling through the 2–3 off days per week protocol, which prevents GHSR-1a downregulation without requiring complete cessation. If you've been dosing MK-677 daily for 4+ weeks and notice diminished GH response (reduced morning appetite, less vivid dreams, stable IGF-1 despite continued dosing), take 7–10 days completely off MK-677 to restore receptor sensitivity, then resume at 4–5 days per week.

Inject CJC-1295 in the morning (6–10 AM) on a fixed day each week to align its peak effect window (48–72 hours post-injection) with mid-week when you're most likely to maintain consistent training and nutrition. Morning injection also allows you to monitor for acute side effects (injection site reaction, flushing, mild nausea) during waking hours rather than overnight. There is no circadian dependence for CJC-1295's mechanism — GHRH receptors don't fluctuate significantly across the 24-hour cycle — so morning versus evening timing is primarily a practical consideration rather than a pharmacological one.

Yes, but expect the primary effect to be fat loss preservation and lean mass retention rather than tissue growth. Growth hormone's effects are context-dependent: in a caloric deficit, elevated GH increases lipolysis (fat breakdown) and reduces protein oxidation (muscle breakdown), but it cannot drive net protein synthesis when total energy and amino acid availability are insufficient. Research from Clemmons et al. in the Journal of Clinical Endocrinology & Metabolism found that GH administration during caloric restriction preserved lean mass and accelerated fat loss compared to placebo, but absolute lean mass did not increase. Use CJC-1295 at 1mg weekly and MK-677 at 12.5mg 4 nights per week during a deficit to minimize the appetite surge that complicates adherence.

MK-677 is not hepatotoxic — it is not metabolized through cytochrome P450 pathways and does not elevate liver enzymes (ALT, AST) in clinical trials at doses up to 25mg daily for 12+ months. Kidney function markers (creatinine, BUN, eGFR) also remain unchanged in healthy individuals. The confusion arises because MK-677 increases GH and IGF-1, which can worsen pre-existing kidney disease by accelerating glomerular hyperfiltration — but this is an effect of elevated GH/IGF-1, not direct MK-677 toxicity. Individuals with chronic kidney disease (CKD Stage 3 or higher) or elevated baseline creatinine should avoid MK-677 entirely; healthy individuals with normal renal function can use it safely at standard research doses.

Measurable indicators include serum IGF-1 elevation (test fasted morning levels at baseline, week 4, and week 8 — expect 30–60% increase from baseline), improved sleep quality (deeper REM cycles, more vivid dreams within 3–5 days of starting MK-677), increased morning appetite (ghrelin effect persists 8–10 hours after evening MK-677 dose), faster nail and hair growth (noticeable after 4–6 weeks), and lean tissue fullness (glycogen supercompensation and intramuscular water retention, detectable within 2–3 weeks). Body composition changes — measurable fat loss or lean mass gain — typically require 8–12 weeks of consistent use paired with appropriate training and nutrition.

CJC-1295 is injected subcutaneously and is unaffected by food intake — inject at any time regardless of meal timing. MK-677 should be taken orally on an empty stomach (2+ hours after last meal) to maximize absorption and GH response, then avoid carbohydrate intake for 1–2 hours post-dose to minimize the transient insulin resistance that occurs during the GH elevation window. Taking MK-677 with food, especially high-fat or high-carbohydrate meals, delays gastric absorption and blunts peak GH elevation by 20–30%. Dosing MK-677 1–2 hours before bed on an empty stomach aligns with natural nocturnal GH secretion and allows you to sleep through the appetite surge.

If you miss a weekly CJC-1295 injection by 1–2 days, administer it as soon as you remember and continue your regular weekly schedule from that new day — the 6–8 day half-life provides flexibility. If you miss by 4+ days, skip the missed dose entirely and resume on your next scheduled injection day to avoid cumulative plasma buildup. If you miss an MK-677 dose, simply continue with your next scheduled evening dose — do not double-dose to 'make up' for the missed day, as this increases the risk of severe appetite surge and glucose dysregulation without providing additional GH benefit.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA